General Information of Drug (ID: DMKNRYH)

Drug Name
AKB-9778 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diabetic macular edema 9B71.02 Phase 2 [1]
Peripheral arterial disease BD4Z Phase 2 [2]
Cross-matching ID
PubChem CID
46700782
CAS Number
CAS 1008510-37-9
TTD Drug ID
DMKNRYH

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin 1 receptor (TEK) TT9VGXW TIE2_HUMAN Activator [1]
Protein tyrosine phosphatase beta (PTPRB) TT64I9Q PTPRB_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Angiopoietin 1 receptor (TEK) DTT TEK 5.194 5.051 6.613 4.982
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic macular edema
ICD Disease Classification 9B71.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiopoietin 1 receptor (TEK) DTT TEK 4.92E-03 0.29 0.84
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02387788) Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO. U.S. National Institutes of Health.
3 Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.J Natl Cancer Inst.2013 Aug 21;105(16):1188-201.